Kornimate/medical-research-clean huggingface dataset:
the effects of normobaric hypoxia on blood glucose levels.

Conditions: Glucose

Summary: the purpose of this research study is to observe whether there is a change in blood glucose levels in response to a 2 hour oral glucose tolerance tests (ogtt) during acute normobaric hypoxia (short term low oxygen levels at normal ambient air pressure).


Eligibility criteria:
inclusion criteria (non-diabetics): * tricare insurance beneficiary (military insurance) receiving care at nellis afb * 5 males with a bmi \ 25 at least 18 years of age (mofh personnel and dod beneficiaries). * 5 females with a bmi \ 25 at least 18 years of age (mofh personnel and dod beneficiaries). exclusion criteria (non-diabetics): * history of abnormal fasting glucose. * pulmonary disease. * any medications that change glucose control to include systemic steroid and diabetic medications. * history of claustrophobia. * pregnant or breast feeding. * non-english speaking. * physical inability to wear/use the robd2 inclusion criteria (diabetics): -5 males and/or females, at least 18 years of age, that are type 2 diabetics (mofh personnel and dod beneficiaries). exclusion criteria (diabetics): * pulmonary disease. * history of claustrophobia. * pregnant or breast feeding. * non-english speaking. * physical inability to wear/use the robd2

Keywords: altitude glucose
phase ii study of therapy with ps 341 in patients with advanced stage non small cell lung cancer

Conditions: Non-small Cell Lung Cancer

Summary: the purpose of this study is to develop new treatments that will hopefully result in the relief of symptoms and prolongation of life. for this reason, your doctors have offered you treatment with a new experimental drug called ps 341.


Eligibility criteria:
inclusion criteria: * patients must have confirmed nsclc (squamous, adeno- and large cell anaplastic carcinoma)stage iii b or stage iv. no prior chemotherapy regimen patients must have adequate organ and marrow function exclusion criteria: * untreated symptomatic brain metastasis patients with known hiv positivity
wheat germ supplementation will improve markers of gut health, inflammation, and insulin resistance in overweight adults

Conditions: Overweight; Insulin Resistance; Inflammation

Summary: the objective of this pilot study is to determine the effects of wheat germ (wg) supplementation on gut health and subsequent effects on markers of inflammation and insulin resistance in overweight individuals. wg is a by-product of wheat processing and an excellent source of omega-3 fatty acids, vitamin e, and fiber. a few studies have shown the health benefits of wg including gut modulatory potential, but the prebiotic functions of wg in humans remain in question and warrant further investigation.

healthy overweight (body mass index, bmi, between 25.0 - 30 kg/m2) between 18 to 45 years old regardless of gender will be recruited. they will be randomly assigned to receive two energy balls containing 30 grams of wheat germ or corn meal (control) in a 4-wk randomized controlled pilot trial. the energy balls will contain wheat germ or corn meal, peanut butter, honey and milk. participants will be asked to consume two energy balls daily for 4 weeks. anthropometric measures, questionnaires (medical, diet, physical activity and bowel habits), blood and fecal samples will be collected at baseline and at the end of the four week study. the investigator's primary outcome variables will be changes in fecal bacteria, immunoglobulin a, zonulin and short chain fatty acids while secondary outcome variables will be alterations in plasma markers of inflammation and insulin resistance.

Eligibility criteria:
inclusion criteria: healthy overweight (body mass index, bmi, between 25.0 - 30 kg/m2) 18-45 years old exclusion criteria: diagnosed diabetes, heart disease, and cancer tobacco use excessive alcohol use taking mega-doses of antioxidant/vitamin supplements or medications that could interfere with study endpoints such as antibiotics, anti-inflammatory, and glucose-lowering medications major surgery occurring within 6 months pregnant or lactating previous high intake of wheat germ or sensitivity to gluten and wheat products.

Keywords: wheat germ overweight gut microbiome inflammation insulin resistance
smoking cessation in alcoholics

Conditions: Smoking Cessation; Alcohol Consumption

Summary: most alcohol-dependent individuals are heavy smokers. the aim of this study is to evaluate whether a specific smoking cessation program (based on cognitive-behavioral therapy) for inpatient alcohol-dependent smokers is more effective than a control condition (treatment as usual).

the study is designed as a randomised, controlled trial conducted in an inpatient alcohol treatment institution. shortly after alcohol detoxification, smokers are offered to voluntarily participate in a smoking cessation program. participation is possible if patients either want to stop smoking or to reduce their consumption for at least 50%. patients are asked about their smoking behaviour at the following time points: at admission (t0), after finishing the smoking cessation program or the control condition (t1), one month later by phone (t2) and six months later in a closing meeting (t3). urine samples and co-breath controls are taken to check both nicotine and alcohol abstinence.

Eligibility criteria:
inclusion criteria: * alcohol-dependent * smoker * intend to stop or reduce smoking for at least 50% exclusion criteria: * taking part in another smoking cessation program * being pregnant * not able to understand instruction due to cognitive impairment

Keywords: smoking alcohol outcome harm reduction alcohol drinking treatment outcome treatment effectiveness
prognosis predicting of crc patients based on morphology and molecular biomaker of ctc

Conditions: Colorectal Cancer; Circulating Tumor Cell

Summary: detecting circulating tumor cells from i-iv stage colorectal cancer patients pre-and post-operatively. analyzing the morphology and biomarkers of ctcs and builting prognosis predicting model based on the morphology and biomarkers of ctcs. verifying the prognosis model by the survival data.


Eligibility criteria:
inclusion criteria: * age 18-80 years; histologically proven colorectal carcinoma (tnm stage i-iv) r0 resection is possible according to preoperative evaluation written informed consent for participation in the trial. exclusion criteria: * primary tumor or metastases not able to be removed radically receiving any preoperative treatment (including chemotherapy, radiotherapy and target therapy) have other malignant tumors meanwhile other previous malignancy within 5 years
study of et140203 t cells in adults with advanced hepatocellular carcinoma (arya-1)

Conditions: Hepatocellular Carcinoma; Liver Cancer; Liver Neoplasm; Metastatic Liver Cancer

Summary: open-label, dose escalation, multi-center, phase i / ii study to assess the safety of an autologous t-cell product (et140203) in adult subjects with alpha-fetoprotein (afp)-positive/human leukocyte antigen (hla) a-2-positive advanced hepatocellular carcinoma (hcc).

the purpose of this study is to investigate an autologous t-cell therapy for advanced hepatocellular carcinoma (hcc). et140203 t cells are autologous t cells genetically modified to carry a tcr-mimic (tcrm) construct capable of mediating cell killing by targeting tumor specific intracellular antigens and addressing solid tumor therapy challenges.

Eligibility criteria:
inclusion criteria: * histologically confirmed hcc with serum afp \>100ng/ml at time of screening and following most current line of therapy or radiographic diagnosis of hcc with serum afp \>400ng/ml at time of screening and following most current line of therapy. * metastatic or locally advanced, unresectable hcc * must have failed or not tolerated at least two (2) different anti-hcc systemic agents * molecular human leukocyte antigen ("hla") class i allele typing confirms participant carries at least one hla-a2 allele * life expectancy of at least 4 months * karnofsky performance scale greater than or equal to 70 * at least 1 measurable lesion on imaging by recist * child-pugh a6 or better * absolute neutrophil count greater than or equal to 1,500/mm\^3 * platelet count greater than or equal to 75,000/mm\^3 exclusion criteria: * clinically significant cardiac disease * clinically significant pre-existing illness or active infection * clinically significant central nervous system (cns) or neural dysfunction * active autoimmune disease requiring therapy * active malignancy other than hcc with the exception of cholangiocarcinoma (cca) or any malignancy with an expected survival ≥ 3 years without any treatment (exception: hormone/androgen-deprivation therapy) and without any organ involvement * history of organ transplant * compromised circulation in portal vein, hepatic vein, or vena cava due to obstruction * advanced hcc involving greater than 50% of the liver

Keywords: hepatocellular carcinoma hcc advanced hcc late-stage hcc liver cancer liver neoplasm metastatic liver cancer metastatic hcc t-cell therapy immunotherapy
effect of postprandial hyperglycemia on vasculature in type 1 diabetes and healthy adults

Conditions: Type 1 Diabetes; Hyperglycemia, Postprandial

Summary: to the investigator's knowledge, there are no data available in the current literature regarding the acute effects of postprandial hyperglycemia and insulin timing on myocardial perfusion in people with type 1 diabetes (t1d). observational studies using ceu in type 2 diabetes demonstrate that postprandial hyperglycemia determines myocardial perfusion defects. the investigator hypothesizes that the combination of postprandial hyperglycemia and insulin increases pulse wave velocity (i.e., aortic stiffness) and myocardial vasoconstriction, thereby reducing myocardial perfusion in t1d when compared to healthy controls. furthermore, the investigator hypothesizes in t1d that dosing insulin before meal intake will ameliorate these cardiovascular defects.

the investigator will compare 17 t1d and 17 age-, sex-, and bmi-matched healthy controls (18-35 yrs) measuring pulse wave velocity (pwv), flow-mediated dilation (fmd) and myocardial perfusion (contrast enhanced ultrasound \[ceu\]) before and 2 hours after ingesting a mixed meal (40% of each subject's daily estimated caloric need, with 50%, 30%, 20% from carbohydrates, fat and protein, respectively). t1d participants will have 2 study admissions: a) injection of insulin 15 minutes before ingesting a mixed meal. b) injection of insulin 15 min after ingesting a mixed meal.

Eligibility criteria:
inclusion criteria: * healthy with no chronic illness * age 18-35 years * bmi ≤ 30 (wt kg/ht m2) * normal screening labs or no clinically significant values * t1d participants must have t1d based on who diagnostic criteria for \> 1 year * a fasting plasma glucose level \>126 mg/dl (7.0 mmol/l) * a casual plasma glucose \>200 mg/dl (11.1 mmol/l) * in the absence of unequivocal hyperglycemia, the diagnosis must be confirmed on a subsequent day. * subjects using sensor-augmented insulin pump therapy and/or artificial pancreas (closed loop system) will be included exclusion criteria: * • smoking presently or have quit \< 2 years. * bp \>140/90 mmhg * bmi \>30 (wt kg/ht m2) * pulse oximetry \<90% * elevated ldl cholesterol \> 160 mg/dl * hba1c ≥ 9 % * use of statins, calcium channel blocker, ace, arb, nitrates, alpha-beta blockers or diuretics * history of cardiac, cerebrovascular, gastrointestinal, liver, renal decease or cancer * presence of an intracardiac or intrapulmonary shunt (we will screen for this by auscultation during the physical exam by pi). * retinopathy (beyond mild non proliferative retinopathy) * urine albumin/creatinine ratio \> 300 mg per g * pregnant or breastfeeding. * known hypersensitivity to perflutren (contained in definity
a prospective study of airless tubing in an inpatient acute hemodialysis unit in hospitalized patients

Conditions: End Stage Renal Failure on Dialysis; Complication of Dialysis; Blood Coagulation Disorders

Summary: the introduction of unfractionated heparin (ufh), which prevents clotting of the extracorporal circuit, was one of the key advances that led to the rapid development and expansion of hemodialysis services. however, anticoagulation during hemodialysis of the patient at high risk for bleeding remains a frequently encountered problem in both inpatient and outpatient dialysis practice. streamline bloodlines are designed to eliminate blood-air contact. this is thought to help reduce heparin use and decrease clotting rates. the goal of this study was to prospectively examine impact of the streamline airless blood tubing set, in an inpatient setting, on dialysis circuit clotting rates, anticoagulation use, and dialysis efficiency.

the introduction of unfractionated heparin (ufh), which prevents clotting of the extracorporeal circuit, was one of the key advances that led to the rapid development and expansion of hemodialysis use, and remains the mainstay in hemodialysis practice today. however, anticoagulation during hemodialysis of the patient at high risk for bleeding remains a frequently encountered problem in the nephrology practice. the need for anticoagulation to prevent clotting of the extracorporeal blood circuit and the need to prevent anticoagulation related bleeding complications in the patient has led to the development of numerous strategies; the safest from a bleeding standpoint being anticoagulant-free hemodialysis. streamline® bloodlines (medisystems® corporation, lawrence, ma) are designed to eliminate blood-air contact. a pressure pod measures arterial and venous pressures without any blood-air contact. the venous chamber is run without an air gap. it is also designed so that blood flows in a circular vortex manner. this airless system is thought to provide several benefits: improved dialysis efficiency and blood flow rates, reduced heparin use and clotting rates. the goal of this study was to prospectively examine the streamline® airless tubing system in an inpatient setting and its association with clotting rates, and dialysis efficiency.

Eligibility criteria:
inclusion criteria: * all adult non-pregnant patients requiring inpatient hemodialysis at our center during the recruitment period until the target sample of dialysis sessions (n=1200) was reached. exclusion criteria: * pregnant females * children

Keywords: hemodialysis dialysis renal dialysis clotting coagulation blood lines
sleep satisfaction and psychomotor performance of adults

Conditions: Sleep Disorders

Summary: primary objective: to assess sleep satisfaction before and after zolpidem cr (ambien cr) administration secondary objective: to assess psychomotor performance before and after zolpidem cr (ambien cr) administration


Eligibility criteria:
inclusion criteria: * patients consulting psychiatrists (private or hospital) -whatever the reason for consulting- who present with chronic primary insomnia from the dsm iv (diagnostic and statistical manual - revision 4). * accepting to participate in the study and signing informed consent exclusion criteria: * pregnancy or breastfeeding. * current severe neuropsychiatric disorder (i.e. psychosis, obsessive compulsive disorder, major depression, dementia of alzheimer or vascular type) according to dsm iv criteria. * history of substance abuse or dependence (including alcohol) within the past year. * hypersensitivity to zolpidem or its excipients. * severe hepatic insufficiency * severe and/or acute respiratory insufficiency * myasthenia gravis. * otc (over the counter) sleep remedies or prescription sleep medications within 2 weeks or 5 half-life before screening. * severe medical illness. the above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
lifestyle intervention in patients with metastatic prostate cancer

Conditions: Prostate Cancer

Summary: the proposed pilot study aims at determining the feasibility of a lifestyle intervention including adherence to a personalised dietary regimen combined with regular physical activity in patients newly diagnosed with prostate cancer under androgen deprivation therapy.

prostate cancer (pca) is among the most frequent tumor types and is the second deadliest type of cancer in men. pca has a multifactorial aetiology; modifiable environmental factors, including diet and obesity, have been associated with prostate carcinogenesis. furthermore, patients with pca are treated with androgen deprivation therapy (adt), which has negative effects on the cardiovascular system and body composition, particularly on the fat and muscle mass, bone health and psychological wellbeing. data in the current literature suggests that a lifestyle intervention e.g. with targeted and supervised exercise therapy or a dietary intervention with a prudent dietary patternmay positively influence the quality of life and the course of the disease of patients under adt. however, conclusive data is missing. the proposed pilot study aims at determining the feasibility and the effect of a lifestyle intervention including adherence to a personalised dietary regimen combined with regular physical activity in patients newly diagnosed with pca under adt.

Eligibility criteria:
inclusion criteria: * written informed consent according to ich/gcp regulations before registration. * age ≥ 18 years * histology of adenocarcinoma of the prostate * patients with pca receiving adt alone or adt+nht (abiraterone, enzalutamide, apalutamide or darolutamide) * rising psa (two consecutively rising psa levels \> 25% above nadir at least three weeks apart), with no evidence of clinical or radiographic progression on instrumental evaluation * psa doubling time \> 8 weeks * continuation of ongoing systemic treatment is deemed feasible by treating physician exclusion criteria: * ongoing treatment with docetaxel, cabazitaxel, radionuclides or investigational treatments * evidence of clinical progression or progression of disease on imaging * bone metastases excluding the safety of physical exercise * prior confirmed severe osteoporosis or other diseases affecting the bone with history of fractures * clinically significant cardiovascular disease (i.e. myocardial infarction within 6 months before screening; uncontrolled angina within 3 months before screening; congestive heart failure new york heart association class 3 or 4; history of clinically significant arrhythmias; uncontrolled hypertension indicated by systolic blood pressure \> 170 mm hg or diastolic blood pressure \> 105 mm hg at screening) * clinically significant chronic obstructive pulmonary disease * any concurrent disease or comorbid condition that interferes with the ability of the patient to participate in the study
using vibroacoustic therapy in a patient with co-infection and covid-19

Conditions: SARS CoV 2 Infection

Summary: this article describes a case of successful treatment of a 59-year-old man with sepsis as a result of periprosthetic infection against the background of severe sars-cov-2-19, who was hospitalized for 59 days, 57 of which were in the intensive care unit. vibroacoustic pulmonary therapy, the concept of noninvasive ventilation, syndrome therapy, combination antibiotic therapy taking into account the pathogen and antibiotic sensitivity were used in the treatment.

during the pandemic caused by sars-cov-2-19, the whole world faced difficulties. nevertheless, surgeons had to perform surgical treatment for patients who needed immediate help with a confirmed coronavirus infection \[1, 2, 3\]. periprosthetic joint infection is a severe and undesirable consequence after arthroplasty \[4, 5\]. patients with coronavirus infection and bacterial infection correlate with an unfavorable outcome \[6, 7, 8\] the effect of vibroacoustic therapy in the treatment of various conditions has not been sufficiently studied \[9, 10\]. this clinical case describes the complex therapy of a patient with a periprosthetic infection on the background of sars-cov-2 using a vibroacoustic pulmonary device.

Eligibility criteria:
inclusion criteria: * p/f less 300 torr * covid-19 virus infection exclusion criteria: * children * acute stroke * acute coronary syndrome * dvt * implanted pacemaker * rib fracture * infection on chest

Keywords: periprosthetic joint infection sars-cov-2 co-infections case report. vibroacoustic therapy
effects of whole-body vibration in patients with knee osteoarthritis.

Conditions: Knee Osteoarthristis

Summary: knee osteoarthritis is a chronic joint disease with an impact on quality of life and an increasing incidence what leads to huge costs and burden on the economy. the present study investigates immediate effects of whole-body vibration on pain, neuromuscular performance, and gait quality in patients with knee osteoarthritis. eligible patients (n=20) with knee osteoarthritis grade 2 or 3 on kallgren lawrence will complete a 5 minute wbv training and a control condition in a randomized order (cross over design). pain, maximum strength of the leg flexors and extensors, the chair rise test and gait parameters will be measured directly before and after the intervention/control.


Eligibility criteria:
inclusion criteria: * x-ray confirmed knee osteoarthritis (kallgren-lawrence 2-3) * knee pain (nrs 0-10 \&gt;2) for 3 months and at least 50% of the last 30 days exclusion criteria: * contraindications for wbv (acute injuries of the musculoskeletal system, new joint endoprosthesis, pregnancy, acute thrombosis, epilepsia, cholecystolithiasis, nephrolithiasis, heart pace maker), * other pathologies affecting gait or neuromuscular performance (rheumatic * opioid medications, cortisol medications and intraarticular injections in the knee during the ist 3 months.

Keywords: knee oa whole-body vibration pain physical function gait parameters
simvastatin reduces adiponectin levels and insulin sensitivity

Conditions: Hypercholesterolemia

Summary: we hypothesized simvastatin may reduce adiponectin levels and insulin sensitivity in overweight hypercholesterolemic patients.


Eligibility criteria:
inclusion criteria: * low-density lipoprotein cholesterol levels more than 100 and body mass index more than 23.0 exclusion criteria: * patients with overt liver disease * chronic renal failure * hypothyroidism, myopathy * uncontrolled diabetes * severe hypertension, stroke * acute coronary events * coronary revascularization within the preceding 3 months, or * alcohol abuse.

Keywords: lipophilic statins insulin resistance hypercholesterolemic patients
prevention of suicide in primary care elderly: collaborative trial (prospect)

Conditions: Depression; Suicide, Attempted

Summary: the purpose of this study was to determine the effect of a primary care intervention on reducing suicidal ideation and depression in older patients.

suicide rates are highest in late life; the majority of older adults who die by suicide have seen a primary care physician in preceding months. depression is the strongest risk factor for late-life suicide and for suicide's precursor, suicidal ideation. the aim of the study was to determine the extent to which an intervention taht combined treatment guidelines with care management reduced rates of depression and suicide ideation in older primary care patients. the study randomized 20 primary care practices from new york city, philadelphia, and pittsburgh regions into intervention or usual car. the used a two-stage sampling design that resulted in a representative sample with an oversample of depressed patients (total n=1238 subjects including 598 with a depression diagnosis and 640 with no depression diagnosis). patients were assessed at baseline, 4, 8, 12, 18 and 24 months.

Eligibility criteria:
inclusion criteria: upcoming appointment with primary care clinician exclusion criteria: * inability to give consent * minimental status examination \<18 * ability to communicate in english

Keywords: depression suicide geriatric elderly primary care